Literature DB >> 15565570

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Jeffrey D Browning1, Lidia S Szczepaniak, Robert Dobbins, Pamela Nuremberg, Jay D Horton, Jonathan C Cohen, Scott M Grundy, Helen H Hobbs.   

Abstract

Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), its pathogenesis and clinical significance remain poorly defined. In this study, we examined and compared the distribution of hepatic triglyceride content (HTGC) in 2,287 subjects from a multiethnic, population-based sample (32.1% white, 48.3% black, and 17.5% Hispanic) using proton magnetic resonance spectroscopy. HTGC varied over a wide range (0.0%-41.7%; median, 3.6%) in the population. Almost one third of the population had hepatic steatosis, and most subjects with hepatic steatosis had normal levels of serum alanine aminotransferase (79%). The frequency of hepatic steatosis varied significantly with ethnicity (45% in Hispanics; 33% in whites; 24% in blacks) and sex (42% in white men; 24% in white women). The higher prevalence of hepatic steatosis in Hispanics was due to the higher prevalence of obesity and insulin resistance in this ethnic group. However, the lower frequency of hepatic steatosis in blacks was not explained by ethnic differences in body mass index, insulin resistance, ethanol ingestion, or medication use. The prevalence of hepatic steatosis was greater in men than women among whites, but not in blacks or Hispanics. The ethnic differences in the frequency of hepatic steatosis in this study mirror those observed previously for NAFLD-related cirrhosis (Hispanics > whites > blacks). In conclusion, the significant ethnic and sex differences in the prevalence of hepatic steatosis documented in this study may have a profound impact on susceptibility to steatosis-related liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565570     DOI: 10.1002/hep.20466

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  1264 in total

1.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

2.  Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C.

Authors:  Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine
Journal:  Dig Dis Sci       Date:  2010-05-12       Impact factor: 3.199

3.  High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial.

Authors:  Stefan B Puchner; Michael T Lu; Thomas Mayrhofer; Ting Liu; Amit Pursnani; Brian B Ghoshhajra; Quynh A Truong; Stephen D Wiviott; Jerome L Fleg; Udo Hoffmann; Maros Ferencik
Journal:  Radiology       Date:  2014-11-04       Impact factor: 11.105

Review 4.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

5.  Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.

Authors:  Melissa A Linden; Justin A Fletcher; E Matthew Morris; Grace M Meers; Monica L Kearney; Jacqueline M Crissey; M Harold Laughlin; Frank W Booth; James R Sowers; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

6.  Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis.

Authors:  Melanie Kahle; Marion Horsch; Barbara Fridrich; Anett Seelig; Jürgen Schultheiß; Jörn Leonhardt; Martin Irmler; Johannes Beckers; Birgit Rathkolb; Eckhard Wolf; Nicole Franke; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Susanne Neschen
Journal:  Mol Metab       Date:  2013-08-03       Impact factor: 7.422

7.  Probable NAFLD, by ALT levels, and diabetes among Filipino-American women.

Authors:  Charlene A Wong; Maria Rosario G Araneta; Elizabeth Barrett-Connor; John Alcaraz; Donna Castañeda; Carol Macera
Journal:  Diabetes Res Clin Pract       Date:  2007-08-30       Impact factor: 5.602

8.  Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.

Authors:  Jennifer C Price; Jennifer L Dodge; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan Noworolski; Phyllis C Tien
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

9.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

Review 10.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.